Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101658 | 0.89 | PTGS2 (0.54) | PTGS2CA2 | |
| SCHEMBL3110187 | 0.89 | PTGS2 (0.53) | PTGS2CA2CA4 | |
| SCHEMBL3118389 | 0.87 | PTGS2 (0.54) | PTGS2SLC6A9CA2 | |
| SCHEMBL3114697 | 0.86 | CA2 (0.49) | PTGS2CA2CA4 | |
| SCHEMBL3098615 | 0.82 | CA9 (0.51) | PTGS2CA2CA4 | |
| SCHEMBL3117954 | 0.82 | PTGS2 (0.57) | PTGS2SLC6A9 | |
| SCHEMBL3102832 | 0.79 | CA2 (0.43) | PTGS2CA2CA4 | |
| SCHEMBL3113061 | 0.79 | CA4 (0.53) | PTGS2CA2CA4 | |
| SCHEMBL3109959 | 0.78 | CA2 (0.49) | CA2CA4 | |
| SCHEMBL3106608 | 0.77 | PTGS2 (0.54) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | PTGS2 47/4885SLC6A9 1966/4885CA2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.